🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Locally Advanced Pancreatic Cancer

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation NCT07784374Phase 21 site📍 Shanghai Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH375, GFH276, GFS202A Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082 Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer NCT05424159NA1 site📍 Shanghai Shanghai Proton and Heavy Ion Center · Tests: Carbon ion radiotherapy PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017Phase 19 sites📍 Newport Beach📍 Miami📍 Detroit PanTher Therapeutics · Tests: PTM-101 Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial) NCT05298722NA8 sites📍 Ghent📍 Dendermonde📍 Eeklo University Hospital, Ghent · Tests: Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires. Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328Phase 3333 sites📍 Gilbert📍 Gilbert📍 Peoria NRG Oncology · Tests: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors NCT06440005Phase 17 sites📍 Los Angeles📍 Sarasota📍 St Louis Angiex, Inc. · Tests: AGX101 Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer NCT06205849Phase 11 site📍 La Jolla University of California, San Diego · Tests: IRE + intratumoral mitazalimab (CD40 antibody) injection, NanoKnife A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor NCT05262491Phase 16 sites📍 Beijing📍 Nanchang📍 Jinan Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1 EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab CREO - Microwave Ablation Feasibility Study NCT07817147NA7 sites📍 Gilbert📍 Los Angeles📍 Chicago Banner Health · Tests: EUS-Guided MWA Device Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source NCT02843945Phase 1, Phase 26 sites📍 Tampa📍 Chicago📍 Oak Lawn CivaTech Oncology · Tests: Directional Brachytherapy Source Implant Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors NCT07589205Phase 11 site📍 Tianjin Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tests: Drug: IBI3028 Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer NCT07173387Phase 21 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: NALIRIFOX (liposomal irinotecan-based chemotherapy)., Stereotactic Body Radiation Therapy (SBRT). Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach NCT05764720NA4 sites📍 Birmingham📍 Duarte📍 St Louis Varian, a Siemens Healthineers Company · Tests: Daily Adaptive External Beam Radiation Therapy A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment NCT06453486Phase 22 sites📍 Toronto📍 Montreal University Health Network, Toronto · Tests: High dose radiation therapy AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642Phase 17 sites📍 Scottsdale📍 Sarasota📍 Chicago Avacta Life Sciences Ltd · Tests: AVA6103 Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer NCT05257993Phase 1, Phase 24 sites📍 Gyeonggi-do📍 Seoul📍 Seoul Onconic Therapeutics Inc. · Tests: JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer NCT07575191Phase 1, Phase 21 site📍 Solna Smartwise Sweden AB · Tests: Gemcitabine, Extroducer Infusion Catheter System An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer NCT07589569Phase 22 sites📍 Nanjing📍 Tianjin Shandong Suncadia Medicine Co., Ltd. · Tests: HRS-7058 Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer NCT06850623Phase 210 sites📍 Scottsdale📍 Stanford📍 Boston EXACT Therapeutics AS · Tests: Acoustic Cluster Therapy, Modified FOLFIRINOX Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy NCT05988814Phase 21 site📍 Dijon Centre Georges Francois Leclerc · Tests: FOLFIRINOX treatment Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017Phase 111 sites📍 Los Angeles📍 Los Angeles📍 Los Angeles Nammi Therapeutics Inc · Tests: QXL138AM Injection every 2 weeks by IV Infusion Surgery for Locally Unresectable Pancreatic Cancer NCT07241663n/a1 site📍 Padova Azienda Ospedaliera di Padova · Tests: Questionnaire PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer NCT05524090n/a1 site📍 Amsterdam Academisch Medisch Centrum - Universiteit van Amsterdam (AM… · Tests: Implementation - International best-practice care The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer NCT06861088Phase 33 sites📍 Ventura📍 Miami Lakes📍 Boston Quercis Pharma AG · Tests: Kinisoquin™, Placebo A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 122 sites📍 Santa Monica📍 Atlanta📍 Jefferson Astellas Pharma Inc · Tests: ASP5834, panitumumab Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma NCT06861452Phase 1, Phase 21 site📍 Modena EIR Biotherapies s.r.l. · Tests: RR001
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy